source
- Turn Therapeutics reports faster symptom relief in Phase 2 eczema trialTurn Therapeutics, a California biotech, disclosed interim results from its Phase 2 study of a topical treatment for atopic dermatitis. The analysis of 50 patients indicated that skin symptoms imp…
- J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer studyJohnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…